Psychiatry

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Long-acting injectables improve outcomes in schizophrenia, yet remain underutilized, highlighting the need for earlier, proactive conversations in care.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.

This Q2 psychiatry recaps promising data of COMP360 for treatment-resistant depression, the expansion of clozapine access, and experts weighing in on new data and ethical debates.

At SDPA 2025, Theodore Rosen, MD, discussed various psychological disorders, including delusions of parasitosis, excoriation disorder, dermatitis artefacta, and others.

A single 25 mg dose of synthetic psilocybin led to a significant reduction in depression severity at 6 weeks in the pivotal COMP005 trial for TRD, meeting its primary endpoint.

In this episode of The Gus Alva Perspective, Gus Alva sits down with Roger McIntyre to discuss his highly anticipated keynote address, titled "The Intersection of Metabolism and Mood”, from the upcoming 2025 Southern California Psychiatry Conference.

Jonathan Meyer, MD, previews his session on updates in tardive dyskinesia at the upcoming 2025 Southern California Psychiatry Conference.

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.

Patients with SCAD and comorbid depression had greater rates of heart failure, cerebrovascular disease, acute kidney injury, and atrial fibrillation.

Alva and Meyer offer a glimpse into what attendees can expect in the schizophrenia portion of the Southern California Psychiatry Conference.

Systematic review of 34 randomized trials finds EMDR most effective, though civilians were more likely than veterans to lose their PTSD diagnosis after treatment.

Discover expert insights and practical guidance in psychiatry with The Gus Alva Perspective, our latest expert-led multimedia offering.

Recent psychiatry updates reveal setbacks and breakthroughs in treatment, including Cobenfy's trial results, evolving patient-provider dynamics, and rising binge drinking among young women.

Alto Neuroscience developed an EEG biomarker that predicts placebo response in MDD trials, potentially improving drug effect detection and reducing trial variability.

Cutler told HCPLive it was surprising that a new survey on subcutaneous TEV- ‘749 revealed 50% and 45.5% of nurses and physicians, respectively, preferred intramuscular injections.

Xanomeline and trospium chloride failed to show significant benefit as an adjunctive schizophrenia treatment to typical antipsychotics but showed promise in select subgroups.

Past month binge drinking rates were greater among females 18-25 years of age than males from 2021-2023, reversing trends seen from 2017-2019.

In this Q&A, Augsten discusses treatment strategies, challenges, and non-pharmacological interventions for schizophrenia and bipolar I disorder based on recent survey findings.

Scoping review results suggest AUD medications may improve hepatic outcomes in patients with ALD, but limited research exists on such an association.

Allergy treatment use increases postpartum depression risk in women with allergic rhinitis, a study found.

Q1 2025 featured several regulatory updates in psychiatry, such as esketamine as the first monotherapy for treatment-resistant depression.

This month in review spotlights phase 2 and 3 trials and discovered associations in the psychiatry field.

HCPLive spoke with Levine about what is moving in the psychiatry pipeline and what is to come.